SEC EDGARSep 21$HTFL

Rogers Campbell sold $987K of HTFL

Rogers Campbell (Chief Medical Officer) sold 19,682 shares of Heartflow, Inc. (HTFL) at $50.15 ($0.99M total) on 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Rogers Campbell

Published Sep 21, 2026, 10:19 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 21, 2026, 10:24 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Bearish

medium confidence

Mentioned

$HTFL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLBearishLow

Why it matters

The insider sale provides fresh data on executive holdings, offering a modest trading signal.

Market read

New Form 4 filing reveals insider sell of ~$1M, a modest negative cue for HTFL.

What to watch

Pre-arranged 10b5-1 plan reduces signaling concerns; sale may be routine liquidity need.

Relevance 4/10Novelty 7/10Timing: filing date 2026-09-21

Background

Heartflow, Inc. (HTFL) develops non-invasive cardiac imaging technology. Recent insider activity is disclosed via SEC Form 4.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLBearishMedium confidence

Context

Chief Medical Officer Rogers Campbell sold 19,682 shares for $987,052 via a 10b5-1 plan, reducing his stake to 79,956 shares.

Expected impact

Possible short-term dip as market digests insider sell.

Evidence & confidence

Sale size is under $1M but involves a senior executive; market may view as a modest negative signal.

Market effects

Sector

Minimal impact on the medical device/diagnostics sector.

Regional

Limited to US investors tracking HTFL.

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

Officer
Rogers Campbell
Chief Medical Officer of Heartflow, Inc.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.